Valeo Pharma Q2 2023 Earnings Report

Valeo Pharma EPS Results

• Actual EPS: -C$0.08
• Consensus EPS: -C$0.07
• Beat/Miss: Missed by -C$0.01
• One Year Ago EPS: N/A

Valeo Pharma Revenue Results

• Actual Revenue: $13.56 million
• Expected Revenue: $13.60 million
• Beat/Miss: Missed by -$40.00 thousand
• YoY Revenue Growth: N/A

Valeo Pharma Announcement Details

• Quarter: Q2 2023
• Date: 6/13/2023
• Time: N/A

Valeo Pharma (TSE:VPH), a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic. In addition, the company provides Ametop Gel 4% for skin anesthesia prior to injection or cannulation; Sabizabulin, an antiviral and anti-inflammatory agent for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death; Simbrinza, ophthalmic drops to treat openangle glaucoma or ocular hypertension; Xiidra, a prescription based eye-drop to treat dry eye disease; and Allerject, a portable voice-activated epinephrine injector for emergency treatment of serious allergic reactions. Its primary therapeutic areas include respiratory/allergy, ophthalmology, neurology, oncology, and specialty products. The company was incorporated in 2003 and is based in Kirkland, Canada.